1800 244 735

Helpline (02) 9874 9777

Huntington’s Disease research update

Handwriting Can Help Identify Asymptomatic Huntington’s, Study Suggests.

WORDS Alberto Molano, PhD from Huntington’s Disease News

ANALYSIS OF handwriting movements using a pen tablet and specialised software can accurately distinguish  people with Huntington’s disease who are still asymptomatic from those without the disease, a new study suggests.

The findings also reveal that certain stroke  features  differ significantly between healthy individuals and patients who are already experiencing Huntington’s symptoms.

The research, “Handwriting Movement abnormalities in Symptomatic and premanifest huntington’s Disease,” was published in the journal Movement Disorders Clinical Practice.

Handwriting abnormalities in huntington’s patients were last reported nearly 20 years ago, and included longer stroke duration and greater variability in stroke velocity. among questions still unanswered is whether assessing handwriting movements can help detect abnormalities in the asymptomatic (premanifest) stage of Huntington’s and serve as a predictor of disease progression.

To investigate, researchers at university of California San Diego test- ed whether handwriting abnormalities were associated with clinical features in symptomatic patients, and if such abnormalities could distinguish asymptomatic Huntington’s patients from healthy controls.

The team asked participants to complete five simple tasks: draw simple loops left to right (a string of “l” letters in cursive writing), complex loops (“lleel- lee”), rapid overlay circles, and spirals, and write the  sentence “today is a nice day.”

Participants used a Wacom digitizing  tablet,  a  device  often used by artists to draw on a computer  screen.  the  tablet  has  a special pen and is sensitive to the level of applied pressure, mimicking traditional drawing on paper. Handwriting traces were recorded and analyzed using a specialized software called MovAlyzeR.

The study involved 38 symptomatic patients (mean age of 55 years), 30 asymptomatic individuals at risk for symptomatic disease (45 years), and 25 healthy controls (44 years).

Results revealed significantly longer and more variable stroke du- ration, as well as decreased hand- writing smoothness, and increased and more variable pen pressures in the handwriting of Huntington’s patients compared with the handwriting of the healthy controls.

Longer stroke duration was associated with greater penney burden of pathology (BOP) and CAG × age product, two measures of disease progression. Of note, the CAG × age product is calculated by multiplying the number of CAG repeats by the patient’s age.

CAG repeats are the genetic abnormality in people with huntington’s. Patients may have 36 to more than 120 of these repeats of three DNA building blocks (cytosine, adenine, and guanine) in their HTT gene. The longer this region is, the earlier the symptoms appear and the more severe the disease.

Handwriting abnormalities in Huntington’s patients were last reported nearly 20 years ago...

Data also showed that analysis of certain handwriting features could distinguish asymptomatic patients from controls with 85% accuracy, 90% sensitivity, and 80% specificity. these included greater variability in stroke amplitude, velocity and pen pressure, higher levels of pen pressure, longer stroke durations, and lower velocities for combinations of handwritten circles, sentences, and spirals.

“These findings support the clinical utility of dynamic measures of hand- writing kinematics as a potential early behavioral biomarker in [huntington’s],” the researchers wrote.

However, they cautioned that these results require confirmation, especially those in asymptomatic patients, and that studies in larger groups are still needed.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more